AlphAIalphai — Financial news for AI agents
rttnews.comAUG 311 min read$AIM

AIM ImmunoTech Secures Broad U.S. Patent For Ampligen In Combination With Keytruda; Stock Up

AIM ImmunoTech (AIM) received a U.S. patent for Ampligen combined with Keytruda for cancer treatment, extending protection to 2039. The patent covers multiple cancers, with a focus on pancreatic cancer. AIM's stock rose 3.36% on Friday and 42.92% in pre-market trading.

Original reporting
rttnews.com
Published Aug 31, 2026, 6:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 31, 2026, 6:28 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefTechnology
Primary signal
$AIM
Bullish
medium confidence
Mentioned
$AIM
Relevance
7/10
alphai data visualization · based on rttnews.com
Decision brief

The 30-second read

$AIMBullishLow
01

Why it matters

The patent grant adds a defensive layer to AIM's portfolio, potentially enhancing valuation if clinical milestones are met.

02

Market read

While the immediate price reaction is notable, the longer‑term relevance hinges on clinical progress and commercialization pathways.

03

What to watch

Potential competition from other TLR3 agonists and the need for regulatory approvals could temper upside.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

AIM ImmunoTech is a micro‑cap biotech developing Ampligen, a TLR3 agonist, for multiple solid tumors.

Company-level read

Ticker impact

$AIMBullishMedium confidence
Context

US Patent Office granted a patent for Ampligen combined with Keytruda, extending protection to 2039.

Expected impact

Potential modest upside as investors price in stronger IP protection; short-term rally possible.

Evidence & confidence

Patent grants are material for biotech firms, but the market impact depends on downstream clinical data and commercialization timelines.

Market effects

Sector

Reinforces the value of IP assets in the oncology biotech sector, may prompt peers to highlight their own patents.

Regional

Limited to US biotech investors; no broader regional effect.

Global

Minor, as the news pertains to a micro‑cap with niche oncology focus.

Counterpoint

What could challenge this read

The patent may have limited commercial value without successful trial data; investors could remain cautious.

Key entities

  • company
    AIM ImmunoTech Inc.

    Biotech firm developing Ampligen.

  • drug
    Keytruda (pembrolizumab)

    PD‑1 checkpoint inhibitor used in combination therapy.

Read at source← All news

Related articles

AUG 10
$AIMLow

AIM ImmunoTech Inc. (AIM): Results of Operations and Financial Condition

AIM ImmunoTech Inc. (AIM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CONFIDENTIAL DRAFT NOT FOR IMMEDIATE RELEASE AIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen® Toward Planned Phase 3 Development in Pancreatic Cancer Completed Enrollment and Ampligen Do

SEC EDGAR 8-K2 min
JUL 23
$AIMMedAI 8/10

AIM Stock Soars 42% As Pancreatic Cancer Trial Hits Key Enrollment Milestone Before Schedule — CEO Sees 'Significant Value-Inflection Period' Ahead

AIM ImmunoTech said its Phase 2 pancreatic cancer trial of Ampligen (rintatolimod) plus AstraZeneca’s Imfinzi (durvalumab) after FOLFIRINOX reached final patient enrollment ahead of schedule. The company expects to complete dosing and assess the primary Clinical Benefit Rate endpoint in December 2026, while continuing Phase 3 planning and expanding regulatory and IP efforts.

stocktwits.com4 min
JUL 9
$AIMMed

WA gold project Warrawoona fined $118,000 over threatened bat

Australia’s DCCEEW fined AIM Mining Corporation $118,000 for EPBC breaches at its Warrawoona Gold Project in WA’s Pilbara, tied to failure to protect the threatened Pilbara leaf-nosed bat. The regulator cited groundwater extraction over limits, missing species management steps, and reporting failures. AIM said it paid the fine. Calidus previously operated the project.

abc.net.au4 min
JUN 18
$AIMMed

AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer

AIM ImmunoTech said the final subject has received the first dose in its Phase 2 DURIPANC trial of Ampligen (rintatolimod) plus AstraZeneca’s Imfinzi (durvalumab) for metastatic pancreatic cancer. Primary endpoint analysis is expected to start in Dec. 2026, with topline results in Q1 2027; secondary endpoint analysis in June 2027. The primary endpoint is clinical benefit rate at 24 weeks.

manilatimes.net3 min
JUN 9
$AIMMedAI 8/10

AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American Rules

AIM ImmunoTech Inc. (NYSE American: AIM) said it priced a registered direct offering and concurrent private placement under NYSE American rules for gross proceeds of about $2.65 million. The company will issue 2,554,119 registered shares and 2,554,119 unregistered shares (or pre-funded warrants) plus Class J warrants to buy up to 10,216,476 shares at $0.5189. Ladenburg Thalmann is placement agent; closing expected June 10, 2026. Net proceeds will fund clinical drug supply, trials, Phase 3 activi

manilatimes.net4 min